Green synthesis processes for pharmaceutical intermediates have become a hot research and development focus in the industry.

Release time:2026-01-14 17:16

Green synthesis processes for pharmaceutical intermediates are becoming a hot research and development focus in the industry, a trend driven by multiple factors.


Green synthesis processes for pharmaceutical intermediates are becoming a hot research and development topic in the industry, a trend driven by multiple factors. As global environmental regulations become increasingly stringent, traditional chemical synthesis methods are facing growing pressure to be phased out due to their high energy consumption and significant pollution levels. By leveraging emerging technologies such as biocatalysis, enzyme engineering, and microreactors, green synthesis processes significantly reduce energy consumption and pollutant emissions during production, thereby aligning with the principles of sustainable development.

From a technical perspective, green synthesis processes demonstrate numerous advantages. For example, biocatalysis—which employs enzymes or microorganisms as catalysts—features high selectivity and mild reaction conditions, thereby reducing the formation of byproducts and improving the utilization rate of raw materials. Advances in gene-editing technologies have also made it possible to optimize microbial metabolic pathways, further enhancing both the yield and purity of target products.

Changes in market demand are also driving the development of green synthesis processes. As consumers increasingly favor environmentally friendly products, pharmaceutical intermediate manufacturers need to adopt more eco-friendly production processes to meet market demands. At the same time, green synthesis processes can help companies reduce their environmental compliance costs and enhance their market competitiveness.

In addition, policy support provides strong guarantees for the research and development of green synthesis processes. Governments around the world have been introducing relevant policies to encourage and support enterprises in adopting green production technologies, thereby promoting the green transformation of the pharmaceutical intermediate industry.